PGx Focus NGS Panel

  • Panel Description
  • Test Description
  • CPT Codes
  • Resources

Panel Description

Fulgent's Pharmacogenetic (PGx) tests gives clinicians the tools to better understand how their patients will respond to certain medications.
With PGx testing, it’s possible to tailor medication plans to a patient’s specific genetic makeup. This can lead to reduced medical costs for patients and providers, safer medication plans, and more efficient drug efficacy. The PGx Focus Panel includes genes associated with drug metabolism with high-level evidence and clinically actionable guidelines.
PGx testing can reveal if a person is a fast, normal, or slow metabolizer. A person’s metabolism changes the way their body responds to medication, including:
• Toxicity
Excessive amounts of the drug accumulate in the bloodstream, resulting in ADRs.

• Lack of Efficacy
The bloodstream cannot absorb enough of the drug to achieve a therapeutic effect.

• Hypersensitivity
Normal amounts of the drug enter the bloodstream, but even this is enough to trigger severe reactions in people with hypersensitivity to the medication.
Identify which drug may be most effective before treatment starts
PGx testing can help clinicians choose the most effective drug for each patient, minimize the risk of adverse reactions, and reduce hospitalizations.

Reduce the risk of adverse events related to certain drugs
PGx testing can assess a patient’s risk for adverse drug reactions before they take the medication which can improve patient safety and minimize costs for healthcare facilities.

Adjust and optimize the dose of current medications
PGx testing can help clinicians predict the appropriate dose of medication for their patient. This allows them to create more personalized medication plans to maximize efficacy and
reduce pharmacy costs.

Improved Patient Care
PGx test results become part of a patient’s medical record, allowing physicians to make more informed decisions when prescribing medications for future medical issues.

Test Description

  • Sequencing (included)
  • Del/Dup (included)
10 - 14 days
Call for details
BCHE, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, G6PD, HLA-B, IFNL4, NAT2, NUDT15, RYR1, SLCO1B1, TPMT, UGT1A1, VKORC1 ( 18 genes )
99% at 50x
Blood (two 4ml EDTA tubes, lavender top) or Extracted DNA (3ug in EB buffer) or Buccal Swab or Saliva (kits available upon request)
All sequencing technologies have limitations. Positive results do not imply that there are no other contributors, genetic or otherwise, to this individual’s phenotype, and negative results do not rule out a genetic cause for the indication for testing. Annotations for FDA, PharmGKB, and CPIC guidelines are updated regularly. Official gene names change over time. Fulgent uses the most up to date gene names based on HUGO Gene Nomenclature Committee ( recommendations. If the gene name on report does not match that of ordered gene, please contact the laboratory and details can be provided. Result interpretation is based on the available clinical and family history information for this individual, collected published information, and Alamut annotation available at the time of reporting. This assay is designed and validated for detection of germline variants only. It is not designed or validated for the detection of low-level mosaicism or somatic mutations. This assay will not detect certain types of genomic aberrations such as translocations, inversions, or repeat expansions (eg. trinucleotide or hexanucleotide repeat expansion). Analysis and reporting is limited to the diplotypes/markers explicitly listed on this report. This test cannot rule out the possibility that the tested individual has a rare or uncharacterized phenotype for genes on this panel.

CPT Code 81227, 81232, 81335, 81355

NOTE:  The CPT codes listed on the website are in accordance with Current Procedural Terminology, a publication of the American Medical Association. CPT codes are provided here for the convenience of our clients. Clients who bill for services should make the final decision on which codes to use.


PGx Clinician Flyer
Adverse Drug Reaction Info Sheet